Genscript Biotech Management
Management criteria checks 2/4
Genscript Biotech's CEO is Sherry Shao, appointed in Jul 2021, has a tenure of 3.92 years. total yearly compensation is $3.62M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 0.036% of the company’s shares, worth $1.46M. The average tenure of the management team and the board of directors is 4.5 years and 2.3 years respectively.
Key information
Sherry Shao
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 9.74% |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.04% |
| Management average tenure | 4.5yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$4m | US$352k | -US$67m |
| Jun 30 2024 | n/a | n/a | -US$177m |
| Mar 31 2024 | n/a | n/a | -US$136m |
| Dec 31 2023 | US$2m | US$353k | US$423m |
Compensation vs Market: Sherry's total compensation ($USD3.62M) is below average for companies of similar size in the US market ($USD7.52M).
Compensation vs Earnings: Sherry's compensation has increased whilst the company is unprofitable.
CEO
Sherry Shao (44 yo)
Ms. Weihui Shao, also known as Sherry, is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.8yrs | US$531.00k | 0.015% $ 597.5k | |
| CEO & COO | 3.9yrs | US$3.62m | 0.036% $ 1.5m | |
| Co-Founder | 23.4yrs | US$914.00k | 0.037% $ 1.5m | |
| Co-Founder & Executive Director | 2.5yrs | US$611.00k | no data | |
| Chief Strategy Officer & Executive Director | 4.6yrs | US$384.00k | 0.049% $ 2.0m | |
| Chief Financial Officer | 4.5yrs | no data | no data | |
| General Counsel & Chief Compliance Officer | no data | no data | no data | |
| Head of Corporate Communications | no data | no data | no data | |
| Chief Marketing Officer for GenScript Life Science Group | less than a year | no data | no data | |
| Head of Global Diversity | no data | no data | no data | |
| Head of Sustainability | no data | no data | no data | |
| Company Secretary | 9.8yrs | no data | no data |
Experienced Management: GNNS.F's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.8yrs | US$531.00k | 0.015% $ 597.5k | |
| Co-Founder | 10.1yrs | US$914.00k | 0.037% $ 1.5m | |
| Co-Founder & Executive Director | 3.1yrs | US$611.00k | no data | |
| Chief Strategy Officer & Executive Director | 4.6yrs | US$384.00k | 0.049% $ 2.0m | |
| Independent Non-executive Director | less than a year | US$23.00k | no data | |
| Member of Advisory Board | 1.4yrs | no data | no data | |
| Member of Advisory Board | 5.8yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | US$30.00k | no data | |
| Member of Scientific Advisory Board | 1.3yrs | no data | no data | |
| Independent Non-Executive Director | 6.6yrs | US$86.00k | 0.00043% $ 17.4k | |
| Independent Non-Executive Director | 1.2yrs | US$60.00k | no data | |
| Independent Non-Executive Director | 1.2yrs | US$60.00k | no data |
Experienced Board: GNNS.F's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/07 00:48 |
| End of Day Share Price | 2025/06/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genscript Biotech Corporation is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Yue-Kwong Lui | China Renaissance Securities |
| Shitong Han | Citic Securities Co., Ltd. |